Loarec A, Gutierrez AG, Muvale G, Couto AM, Nguyen AP, et al.
2023-03-30 • Health Science Reports
2023-03-30 • Health Science Reports
BACKGROUND AND AIMS Hepatitis C (HCV) programs face challenges, especially linked to key populations to achieve World Health Organization (WHO) goals of eliminating hepatitis. Médeci...
Swe TM, Johnson DC, Mar HT, Thit P, Homan T, et al.
2023-02-17 • Health Science Reports
2023-02-17 • Health Science Reports
BACKGROUND AND AIMS In Myanmar, public sector treatment programs for hepatitis C virus (HCV) infection were nonexistent until June 2017. WHO highlights the importance of simplificati...
Arago M, Mangue M, Cumbi N, Zamudio AG, Loarec A, et al.
2021-05-20 • MSF Scientific Days International 2021: Innovation
2021-05-20 • MSF Scientific Days International 2021: Innovation
WHAT CHALLENGE OR OPPORTUNITY DID YOU TRY TO ADDRESS? WERE EXISTING SOLUTIONS NOT AVAILABLE OR NOT GOOD ENOUGH? Ototoxicity is an unfortunate side-effect of second-line injectable dr...
Loarec A, Carnimeo V, Molfino L, Kizito W, Muyindike WR, et al.
2018-11-16 • AIDS
2018-11-16 • AIDS
: A multicentric, retrospective case-series analysis (facility-based) in five sites across Kenya, Malawi, Mozambique, and Uganda screened HIV-positive adults for hepatitis C virus (HCV) ...
Mafirakureva N, Lim AG, Khalid GG, Aslam K, Campbell L, et al.
2020-11-04 • Journal of Viral Hepatitis
2020-11-04 • Journal of Viral Hepatitis
Despite the availability of effective direct-acting antiviral (DAA) treatments for Hepatitis C virus (HCV) infection, many people remain undiagnosed and untreated. We assessed the cost-e...
Freiman JM, Wang J, Easterbrook PJ, Horsburgh CR, Marinucci F, et al.
2019-02-21 • Journal of Hepatology
2019-02-21 • Journal of Hepatology
BACKGROUND & AIMS Affordable point-of-care tests for hepatitis C (HCV) viraemia are needed to improve access to treatment in low- and middle-income countries. Our aims were to determ...
Walker JG, Mafirakureva N, Iwamoto M, Campbell L, Kim CS, et al.
2020-05-31 • Liver International
2020-05-31 • Liver International
BACKGROUND & AIMS In 2016, Médecins Sans Frontières established the first general population Hepatitis C virus (HCV) screening and treatment site in Cambodia, offering free direct-ac...
Sema Baltazar C, Kellogg TA, Boothe M, Loarec A, de Abreu E, et al.
2021-04-01 • International Journal of Drug Policy
2021-04-01 • International Journal of Drug Policy
BACKGROUND People who use drugs (PWUD) which includes both people who inject drugs (PWID) and non-injection drug users (NIDU) are marginalized, experience high levels of stigma and d...
Deiss R, Loreti C, Gutierrez AG, Filipe E, Tatia M, et al.
2021-04-26 • PLOS One
2021-04-26 • PLOS One
BACKGROUND Cryptococcal meningitis is a leading cause of HIV-related mortality in sub-Saharan Africa, however, screening for cryptococcal antigenemia has not been universally impleme...
Morgan JR, Marsh E, Savinkina A, Shilton S, Shadaker S, et al.
2022-03-12 • Journal of Viral Hepatitis
2022-03-12 • Journal of Viral Hepatitis
Achieving global elimination of hepatitis C virus requires a substantial scale-up of testing. Point-of-care HCV viral load assays are available as an alternative to laboratory-based assa...
Lynch E, Falq G, Sun C, Bunchhoeung PDT, Huerga H, et al.
2021-02-26 • BMC Infectious Diseases
2021-02-26 • BMC Infectious Diseases
BACKGROUND Despite a dramatic reduction in HCV drug costs and simplified models of care, many countries lack important information on prevalence and risk factors to structure effecti...
Mafirakureva N, Stone J, Fraser H, Nzomukunda Y, Maina A, et al.
2020-06-29 • Society
2020-06-29 • Society
BACKGROUND AND AIMS Hepatitis C virus (HCV) treatment is essential for eliminating HCV in people who inject drugs (PWID), but has limited coverage in resource-limited settings. We me...
Gupta E, Carnimeo V, Samukcham I, Loarec A, Mahajan S, et al.
2018-07-01
2018-07-01
P R O T O C O L S U M M A R Y
Title: Field evaluation of the performance of HCV Serological Rapid Diagnostic Tests among
HCV/HIV co-infected patients.
Aim: To evaluate...
Lim AG, Walker JG, Mafirakureva N, Khalid GG, Qureshi H, et al.
2020-03-01 • Lancet Global Health
2020-03-01 • Lancet Global Health
BACKGROUND The WHO elimination strategy for hepatitis C virus advocates scaling up screening and treatment to reduce global hepatitis C incidence by 80% by 2030, but little is known ...
Marquez LK, Chaillon A, Soe KT, Johnson DC, Zosso JM, et al.
2021-02-01 • BMJ Global Health
2021-02-01 • BMJ Global Health
INTRODUCTION Over half of those hepatitis C virus (HCV)/HIV coinfected live in low-income and middle-income countries, and many remain undiagnosed or untreated. In 2016, Médecins San...
Loarec A, Nguyen AP, Chissano M, Madeira N, Rusch B, et al.
2021-12-02 • Bulletin of the World Health Organization
2021-12-02 • Bulletin of the World Health Organization
OBJECTIVE To pilot an intervention on the prevention of mother-to-child transmission (PMTCT) of hepatitis B virus (HBV) in an antenatal care and maternity unit in Maputo, Mozambique,...
